Ranjit Shahani, vice chairman and managing director of Novartis's business in India, criticized the ruling.
WSJ: Novartis Loses Glivec Patent Battle in India
2.
"It's not just the super-prime" borrowers who are being barraged with new offers, said Anuj Shahani, director of Synovate's Competitive Tracking Services.
WSJ: Banks Loosen Purse Strings
3.
"We have never seen the richness of offers we are seeing today, " said Anuj Shahani, director of key accounts at Mintel Comperemedia, a market research firm.